Osteoclast differentiation and activation
暂无分享,去创建一个
[1] W. Vainchenker,et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. , 2003, Blood.
[2] D. Lacey,et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.
[3] Steven W. Martin,et al. A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases , 2003, Cancer.
[4] Noriaki Yoshida,et al. U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells* , 2002, The Journal of Biological Chemistry.
[5] Hiroshi Takayanagi,et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.
[6] W. Dougall,et al. A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.
[7] E. Wagner,et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms , 2002, Journal of Cell Science.
[8] L. Hofbauer,et al. Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.
[9] B. Riggs,et al. The Immunosuppressant Rapamycin, Alone or with Transforming Growth Factor-b, Enhances Osteoclast Differentiation of RAW264.7 Monocyte-Macrophage Cells in the Presence of RANK-Ligand , 2002, Calcified Tissue International.
[10] T. Takeya,et al. Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator* , 2002, The Journal of Biological Chemistry.
[11] S. Marks,et al. The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[12] H. Yasuda,et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis , 2002, Journal of Bone and Mineral Metabolism.
[13] I. Reid,et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. , 2002, Human molecular genetics.
[14] T. Mak,et al. Immunology: A block at the toll gate , 2002, Nature.
[15] M. Kumegawa,et al. Regulation of Receptor Activator of NF-κB Ligand-induced Osteoclastogenesis by Endogenous Interferon-β (INF-β) and Suppressors of Cytokine Signaling (SOCS) , 2002, The Journal of Biological Chemistry.
[16] T. Nishihara,et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. , 2002, Endocrinology.
[17] Hong-Hee Kim,et al. TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. , 2002, Journal of biochemistry and molecular biology.
[18] Hao Wu,et al. Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.
[19] Ulrich Siebenlist,et al. NF‐κB p50 and p52 Expression Is Not Required for RANK‐Expressing Osteoclast Progenitor Formation but Is Essential for RANK‐ and Cytokine‐Mediated Osteoclastogenesis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] E. Eriksen,et al. Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] Sandrine Bongiovanni,et al. Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFκB* , 2002, The Journal of Biological Chemistry.
[22] J. Baek,et al. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression , 2002, Experimental & Molecular Medicine.
[23] P. Stashenko,et al. c‐myc Is Required for Osteoclast Differentiation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] Kozo Nakamura,et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.
[25] Y. Kadono,et al. Possible Involvement of IκB Kinase 2 and MKK7 in Osteoclastogenesis Induced by Receptor Activator of Nuclear Factor κB Ligand , 2002 .
[26] Michael Karin,et al. NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.
[27] K. Preissner,et al. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[28] Michael C. Ostrowski,et al. Microphthalmia Transcription Factor Is a Target of the p38 MAPK Pathway in Response to Receptor Activator of NF-κB Ligand Signaling* , 2002, The Journal of Biological Chemistry.
[29] C. Murphy,et al. TNFα Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL. , 2002, Endocrinology.
[30] Shi Wei,et al. Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.
[31] N. Sakurai,et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. , 2002, Molecular and cellular biology.
[32] M. Whyte,et al. Expansile Skeletal Hyperphosphatasia Is Caused by a 15‐Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] M. Kumegawa,et al. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. , 2002, The Journal of biological chemistry.
[34] J. Penninger,et al. RANK-L and RANK: T cells, bone loss, and mammalian evolution. , 2002, Annual review of immunology.
[35] Matthew J. Silva,et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Network Boston.
[36] S. Khosla,et al. Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.
[37] B. Olsen,et al. Mouse models of abnormal skeletal development and homeostasis. , 2001, Trends in genetics : TIG.
[38] E. Wagner,et al. Genetic control of skeletal development. , 2001, Current opinion in genetics & development.
[39] Y. Kadono,et al. Segregation of TRAF6‐mediated signaling pathways clarifies its role in osteoclastogenesis , 2001, The EMBO journal.
[40] A. Nakanishi,et al. The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[41] B. Riggs,et al. Regulation of osteoclastogenesis and RANK expression by TGF‐β1 , 2001 .
[42] R. L. Cain,et al. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. , 2001, Endocrinology.
[43] Hiroshi Takayanagi,et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.
[44] M. Tsujimoto,et al. Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)* , 2000, The Journal of Biological Chemistry.
[45] T. Martin,et al. Therapeutic approaches to bone diseases. , 2000, Science.
[46] T. Chambers. Regulation of the differentiation and function of osteoclasts , 2000, The Journal of pathology.
[47] S. Teitelbaum,et al. Bone resorption by osteoclasts. , 2000, Science.
[48] T. Martin,et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. , 2000, Endocrinology.
[49] D L Lacey,et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. , 2000, The American journal of pathology.
[50] D L Lacey,et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[51] Sundeep Khosla,et al. The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[52] R. Wallace,et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.
[53] T. Miyata,et al. Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.
[54] H. Hanafusa,et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.
[55] Yuqiong Liang,et al. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification , 1999, Nature Genetics.
[56] W. Dougall,et al. RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.
[57] S. Morony,et al. A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL‐1β, TNF‐α, PTH, PTHrP, and 1,25(OH)2D3 , 1999 .
[58] E. Jimi,et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. , 1999, Journal of immunology.
[59] D. Lacey,et al. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.
[60] S. Morony,et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.
[61] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[62] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[63] Josef M. Penninger,et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.
[64] H. Yasuda,et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.
[65] W. Dougall,et al. The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.
[66] G. Rodan. Bone homeostasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[67] B. Aggarwal,et al. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. , 1998, The Journal of biological chemistry.
[68] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[69] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[70] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[71] S. Mochizuki,et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.
[72] Ulrich Siebenlist,et al. Requirement for NF-κB in osteoclast and B-cell development , 1997 .
[73] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[74] Brian R. Wong,et al. TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.
[75] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[76] E. Wagner,et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.
[77] S. Marks,et al. Osteoclast biology: lessons from mammalian mutations. , 1989, American journal of medical genetics.
[78] Sheila J. Jones,et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. , 1988, Endocrinology.